{"id":"NCT01332994","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis","officialTitle":"Efficacy and Safety Study of a Sequential Therapy of Tocilizumab (TCZ) and, if Initially Inadequately Responded to Tocilizumab (TCZ), Followed by Rituximab (RTX) in DMARD-IR Patients With Rheumatoid Arthritis (MIRAI)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2014-02","completion":"2014-02","firstPosted":"2011-04-11","resultsPosted":"2015-09-07","lastUpdate":"2015-09-07"},"enrollment":519,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"rituximab [MabThera/Rituxan]","otherNames":[]},{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]},{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"This open-label, multi-center, two-arm, uncontrolled and non-randomized study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Patients will receive 8 mg/kg RoActemra/Actemra intravenously every 4 weeks for 12 weeks and - if adequately responded - for further 12 weeks. Patients, who show an inadequate clinical response after the first 12 weeks to RoActemra/Actemra, will receive 1 g MabThera/Rituxan (rituximab) intravenously at Week 16 and 18. The anticipated time of study treatment is 32 weeks.","primaryOutcome":{"measure":"Percentage of Participants Achieving Remission at Week 16 According to DAS28","timeFrame":"Week 16","effectByArm":[{"arm":"TCZ/TCZ or TCZ/RTX","deltaMin":42.8,"sd":null}],"pValues":[{"comp":"OG000","p":"0.1648"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":83,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":54,"n":519},"commonTop":["Nasopharyngitis","Hypertension"]}}